Skip to content

Scilex Holding Company SCLX Cash & Equivalents

Cash & Equivalents at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$289.56M+147%
Viatris logo
ViatrisVTRS
$1.81B+139%
PTH
Pelthos Therapeutics Inc.PTHS
$31.98M+24,250%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$24.47M-46.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$95.6M+156%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$175M+37.8%

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.4%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Reported directly by Scilex Holding Company in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's cash & equivalents?
Scilex Holding Company (SCLX) reported cash & equivalents of $3.35M in Q1 2026.
How has Scilex Holding Company's cash & equivalents changed year-over-year?
Scilex Holding Company's cash & equivalents decreased by 42.2% year-over-year, from $5.8M to $3.35M.
What is the long-term trend for Scilex Holding Company's cash & equivalents?
Over 5 years (2020 to 2025), Scilex Holding Company's cash & equivalents has grown at a 176.8% compound annual growth rate (CAGR), from $30.51K to $4.96M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.